Baxter International is a healthcare company that focuses on developing and providing a wide range of medical products and services to enhance patient care. The company specializes in creating innovative therapies and solutions for various health conditions, including renal and hospital care. With a strong emphasis on sustainability and improving patient outcomes, Baxter manufactures essential medical devices, pharmaceuticals, and biotechnology products that support the treatment of chronic diseases and acute medical conditions. Their commitment to research and development drives advancements in healthcare technology, helping to meet the needs of healthcare professionals and patients worldwide. Read More
Shares of healthcare company Baxter International (NYSE:BAX)
fell 20% in the afternoon session after the company reported disappointing second-quarter results and cut its full-year profit forecast, citing the lingering impact of a hurricane. The healthcare company pointed to the lingering effects of Hurricane Helene, which damaged a key manufacturing facility and disrupted the supply of its IV solutions. Baxter’s adjusted earnings per share of 59 cents missed analysts' estimates, while revenue of $2.81 billion also came in slightly below expectations. In response to these challenges and what management called demand softness, the company lowered its full-year profit guidance. The weak results and revised outlook prompted a negative reaction from investors.
Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Healthcare company Baxter International (NYSE:BAX) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 4.3% year on year to $2.81 billion. On the other hand, next quarter’s revenue guidance of $2.87 billion was less impressive, coming in 1% below analysts’ estimates. Its non-GAAP profit of $0.59 per share was 3.2% below analysts’ consensus estimates.
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2025 financial results on Thursday, July 31, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I156238 to pre-register for the call and receive the call information.
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on October 1, 2025, to stockholders of record as of August 29, 2025. The indicated annual dividend rate is $0.68 per share of common stock.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Hider will take up his responsibilities no later than Sept. 3 or at an earlier date after completing his current commitments at ATS Corporation (ATS), Baxter said.
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its 2024 Corporate Responsibility Report. The annual report demonstrates Baxter's commitment to transparent reporting and provides updates on the company’s 2030 Corporate Responsibility Commitment and Goals,1 which strive to create a more sustainable and responsible business model.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
